Coronavirus Vaccine Efficacy Rate Set At 50% Because That’s What US FDA ‘Could Tolerate’

 
• By Derrick Gingery

CBER Director Marks explains that too high a bar might result in natural herd immunity before vaccine trials could be completed, while too low a threshold could result in approval of products with limited efficacy.

Accelerated approval may not be appropriate for early coronavirus vaccine candidates, CBER Director Peter Marks said in an up-close look at FDA’s decision-making as it developed its guidance. • Source: Screenshot

More from Vaccines

More from Pink Sheet